Gilead Sciences' patent on hepatitis C drug sofosbuvir challenged in Delhi High Court Our Bureau, Mumbai
Tuesday, May 17, 2016, 08:00 Hrs [IST]
The US-based Initiative for Medicines, Access & Knowledge (I-MAK) and the Delhi Network of Positive People (DNP+) have filed an appeal with the Delhi High Court challenging the Delhi Patent Office's decision to accord patent to US pharma company Gilead Sciences' blockbuster hepatitis C (HCV) drug sofosbuvir.
In their appeal, these health groups have pleaded that the Indian patent office's latest decision is contrary to the public interest, fails to assess the full scientific and legal evidence presented and ignores key Indian patent law and judicial precedents. Gilead has claimed existing public knowledge as its own and its patent on sofosbuvir, the base compound in its Hep C drug Sovaldi, is 'unmerited', these groups said.
Continue reading...
No comments:
Post a Comment